Bivalirudin and Desmopressin Market Size

Bivalirudin and Desmopressin Market size is projected to growing at around 5.1% CAGR during the forecast period i.e., between 2024-2036. Increasing demand for bivalirudin is being driven by its application in the treatment of cancer and cardiovascular disease. In addition, rising incidences of cardiovascular diseases worldwide are expected to drive bivalirudin and desmopressin market growth during the forecast period. According to the World Health Organization, Cardiovascular disease is one of the leading causes of death worldwide. CVDs caused an estimated 17.9 million deaths in 2019, which accounted for 32% of all deaths worldwide. Furthermore, increasing demand for desmopressin owing to its use for nocturia and bedtime wetting is expected to drive global bivalirudin and desmopressin market growth. Desmopressin medicines have also been extensively used in conditions such as diabetes insipidus, which causes the body to produce excessive amounts of urine.

Bivalirudin is a synthetic residue compound that inhibits direct thrombin. Especially in people with severe chest pain or those undergoing angioplasty, it prevents the formation of blood clots. Also, heart attack patients who undergo percutaneous coronary intervention are treated with this drug. Likewise, desmopressin is an artificial replacement for vasopressin and acts by limiting the amount of water that is excreted in the urine. Moreover, awareness programs and initiatives regarding bedwetting and enuresis medical conditions are market trends expected to propel the demand for desmopressin during the forecast period. For instance, in September 2021, an organization launched a public awareness campaign to raise awareness about the problem of enuresis in children.